Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji K Kumar, Angela Dispenzieri, Sagar Lonial, Brian G.M. Durie, Paul G. Richardson, Saad Z Usmani, Antje Hoering, Robert Z Orlowski

Blood blood.2024025939.

https://doi.org/10.1182/blood.2024025939

Published: 2024

Includes: Supplemental data

Journal Articles

Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort

Blood (2022) 140 (Supplement 1): 266–267.

https://doi.org/10.1182/blood-2022-170166

Published: 2022

Journal Articles

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Hans C. Lee, Rafat Abonour, Sikander Ailawadhi, Brian G.M. Durie, Cristina J. Gasparetto, James W. Hardin, Mohit Narang, James Omel, Robert M. Rifkin, Howard Terebelo, Kathleen Toomey, Lynne I. Wagner, Samantha Slaff, Dailan Danforth, Weiyuan Chung, Jasmeet Anand, Edward Yu, Derek Tang, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 13256–13258.

https://doi.org/10.1182/blood-2022-158197

Published: 2022

Journal Articles

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

Joshua Richter, Sikander Ailawadhi, Hans C. Lee, James W. Hardin, Howard R. Terebelo, Rafat Abonour, Lynne I. Wagner, Brian G.M. Durie, James L. Omel, Mohit Narang, Kathleen Toomey, Robert M. Rifkin, Cristina J. Gasparetto, Edward Yu, Jasmeet Anand, Liang Liu, Ying-Ming Jou, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 8089–8091.

https://doi.org/10.1182/blood-2022-158627

Published: 2022

Journal Articles

Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Blood (2022) 140 (Supplement 1): 7166–7167.

https://doi.org/10.1182/blood-2022-168741

Published: 2022

Journal Articles

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Shaji K Kumar, Melissa Alsina, Betsy Laplant, Ashraf Z. Badros, Al-Ola Abdallah, Rafat Abonour, Erik J Asmus, Binod Dhakal, Cara A. Rosenbaum, Daniel Egan, Manisha Bhutani, Andrzej Jakubowiak, Brian G.M. Durie

Blood (2022) 140 (Supplement 1): 1830–1832.

https://doi.org/10.1182/blood-2022-168930

Published: 2022

Journal Articles

Post-Hoc Analysis of Efficacy and Safety in the SWOG S0777 Trial Stratified By Age

Brian G.M. Durie, Annette Lam, Mai Ngo, Huiling Pei, Eric M. Ammann

Blood (2022) 140 (Supplement 1): 10009–10010.

https://doi.org/10.1182/blood-2022-165591

Published: 2022

Journal Articles

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

Rajshekhar Chakraborty, Rachael Sexton, Suzanne Lentzsch, Muneer H. Abidi, Peter M. Voorhees, Adam D Cohen, Eric Rohren, Stephen B. Heitner, Kevin R. Kelly, Niklas J Mackler, David M. Baer, Antje Hoering, Brian G.M. Durie, Sikander Ailawadhi, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 4349–4351.

https://doi.org/10.1182/blood-2022-166609

Published: 2022

Journal Articles

Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study

Blood (2022) 140 (Supplement 1): 261–263.

https://doi.org/10.1182/blood-2022-157138

Published: 2022

Journal Articles

Circulating RAS/RAF and DNA-Repair Gene Mutations Associates with High-Risk/Treatment Resistance in Primary Refractory Multiple Myeloma

Sridurga Mithraprabhu, John Reynolds, Rose Turner, Hang Quach, Noemi Horvath, Ian H Kerridge, Flora Yuen, Tiffany Khong, Brian G.M. Durie, Andrew Spencer

Blood (2022) 140 (Supplement 1): 9933–9934.

https://doi.org/10.1182/blood-2022-171053

Published: 2022

Journal Articles

Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort

Blood (2022) 140 (Supplement 1): 9923–9924.

https://doi.org/10.1182/blood-2022-168690

Published: 2022

Journal Articles

Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do

Blood (2022) 140 (Supplement 1): 256–258.

https://doi.org/10.1182/blood-2022-163169

Published: 2022

Journal Articles

Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Blood (2022) 140 (Supplement 1): 10108–10109.

https://doi.org/10.1182/blood-2022-170623

Published: 2022

Journal Articles

Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study

Blood (2022) 140 (Supplement 1): 10031–10032.

https://doi.org/10.1182/blood-2022-169393

Published: 2022

Journal Articles

Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study

Blood (2022) 140 (Supplement 1): 10024–10026.

https://doi.org/10.1182/blood-2022-168070

Published: 2022

Journal Articles

Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study

Blood (2022) 140 (Supplement 1): 10099–10100.

https://doi.org/10.1182/blood-2022-168822

Published: 2022

Journal Articles

Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study

Blood (2022) 140 (Supplement 1): 2338–2340.

https://doi.org/10.1182/blood-2022-164758

Published: 2022

Journal Articles

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

Nnadozie Emechebe, Shaji Kumar, Hartmut Goldschmidt, Maria-Victoria Mateos, Juan Du, Kihyun Kim, Giampaolo Merlini, Meletios A. Dimopoulos, Heinz Ludwig, Hiroshi Handa, Carlos Fernandez de Larrea, Donna E. Reece, Wenming Chen, Noopur S. Raje, Sudeep Karve, Emma Arriola, Jeremy A. Ross, Brian G.M. Durie

Blood (2021) 138 (Supplement 1): 4725.

https://doi.org/10.1182/blood-2021-149270

Published: 2021

Journal Articles

Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM) Study

Blood (2021) 138 (Supplement 1): 542.

https://doi.org/10.1182/blood-2021-153827

Published: 2021

Journal Articles

Monitoring of Circulating Tumor Plasma Cells in Patients with Precursor Conditions of Multiple Myeloma: Data from the Prospective Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Jón Þórir Óskarsson, Iris Petursdottir, Sæmundur Rögnvaldsson, Sigrun Thorsteinsdottir, Gudrun Asta Sigurdardottir, Asdis Rosa Thordardottir, Gauti Kjartan Gislason, Andri Olafsson, Brynjar Vidarsson, Pall Torfi Onundarson, Bjarni Agnar Agnarsson, Robert Palmason, Margret Sigurdardottir, Ingunn Thorsteinsdottir, Isleifur Olafsson, Brian G.M. Durie, Thorvardur Jon Love, Sigurdur Y Kristinsson

Blood (2021) 138 (Supplement 1): 2645.

https://doi.org/10.1182/blood-2021-146363

Published: 2021

NARROW

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Post-Hoc Analysis of Efficacy and Safety in the SWOG S0777 Trial Stratified By Age

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study

Circulating RAS/RAF and DNA-Repair Gene Mutations Associates with High-Risk/Treatment Resistance in Primary Refractory Multiple Myeloma

Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort

Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do

Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study

Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study

Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study

Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM) Study

Monitoring of Circulating Tumor Plasma Cells in Patients with Precursor Conditions of Multiple Myeloma: Data from the Prospective Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only